Results 41 to 50 of about 17,281 (197)

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki, Tetsu Watanabe, Mari Shimizu, Shingo Tachibana, Junya Sato, Yuta Kobayashi, Harutoshi Tamura, Shigehiko Kato, Satoshi Nishiyama, Hiroki Takahashi, Takanori Arimoto, Masafumi Watanabe   +11 more
wiley   +1 more source

The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review

ESC Heart Failure, Volume 12, Issue 2, Page 980-997, April 2025.
Abstract Heart failure (HF) creates a considerable clinical, humanistic and economic burden on patients and caregivers as well as on healthcare systems. To attenuate the significant burden of HF, there is a need for enhanced management of patients with HF.
Javed Butler, Malcolm Brown, Philippe Prokocimer, Ashley C. Humphries, Sophie Pope, Olivia Wright, Jun Su, Osama Elnawasany, Bogdan Muresan   +8 more
wiley   +1 more source

Abnormal diastolic function underlies the different beneficial effects of cardiac resynchronization therapy on ischemic and non-ischemic cardiomyopathy

Clinics
OBJECTIVES: To investigate the association between diastolic function and the different beneficial effects of cardiac resynchronization therapy in patients with heart failure due to different causes.
Qi Wang, Kang-Yu Chen, Fei Yu, Hao Su, Chun-Sheng An, Yang Hu, Dong-Mei Yang, Jian Xu, Ji Yan   +8 more
doaj   +1 more source

Improved relationship between left and right ventricular electrical activation after cardiac resynchronization therapy in heart failure patients can be quantified by body surface potential mapping

Clinics, 2013
OBJECTIVES: Few studies have evaluated cardiac electrical activation dynamics after cardiac resynchronization therapy. Although this procedure reduces morbidity and mortality in heart failure patients, many approaches attempting to identify the ...
Nelson Samesima, Carlos Alberto Pastore, Roberto Andrés Douglas, Martino Martinelli Filho, Anísio A. Pedrosa   +4 more
doaj   +1 more source

Safe application of extensive radiotherapy to a cardiac resynchronization device

ESC Heart Failure, 2020
Patients with cardiac implantable electronic devices undergoing radiotherapy (RT) are prone to the risk of device failure. Guidelines and manufacturer's instructions are lacking practical recommendations for cumulative radiation doses to pacemakers or ...
Christiana Schernthaner, Michael Kopp, Karin Dagn, Lukas Rettenbacher, Lukas Weiss, Damian Meyersburg, Mathias‐Christoph Brandt, Uta C. Hoppe, Bernhard Strohmer   +8 more
doaj   +1 more source

Transseptal approach to the implantation of cardiac resynchronization therapy [PDF]

Vojnosanitetski Pregled, 2018
Introduction. In patients with cardiac resynchronization therapy left ventricular lead is usually placed through a tributary vein of the coronary sinus.
Vukmirović Mihailo, Angelkov Lazar, Tomašević-Vukmirović Irena, Vukmirović Filip   +3 more
doaj   +1 more source

2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy

Российский кардиологический журнал, 2022
Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC).With the special contribution of the European Heart Rhythm Association (EHRA).
article Editorial
doaj   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Sex‐Based Differences in Selected Cardiac Implantable Electronic Device Use: A 10‐Year Statewide Patient Cohort

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Cardiac implantable electronic devices (CIEDs) include pacemakers, cardioverter defibrillators, and resynchronization therapy. This study aimed to assess CIED implantation and outcomes by sex and indication.
Kasun De Silva, Natasha Nassar, Tim Badgery‐Parker, Saurabh Kumar, Lee Taylor, Pramesh Kovoor, Sarah Zaman, Andrew Wilson, Clara K. Chow   +8 more
doaj   +1 more source